Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bortezomib→

Bortezomib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
179324-69-7
Molecular formula
C19H25BN4O4
Molecular weight
384.2 g/mol
Drug class
Proteasome Inhibitor
Mechanism of action
Proteasome Inhibitors [MoA]
Indications / reported uses
  • Multiple Myeloma
  • Lymphoma, Mantle-Cell
  • adult patients with multiple myeloma
  • adult patients with mantle cell lymphoma

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bortezomib Environmental Risk Assessment (ERA) (the Bortezomib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.